Optimal Exercise Programs for Patients with Peripheral Artery Disease: A Scientific Statement from the American Heart Association

Diane Treat-Jacobson; Mary M. McDermott; Ulf G Bronas; Umberto Campia; Tracie C. Collins; Michael H. Criqui; Andrew W. Gardner; William R. Hiatt; Judith G. Regensteiner; Kathleen Rich

doi:10.1161/CIR.0000000000000623

Optimal Exercise Programs for Patients with Peripheral Artery Disease: A Scientific Statement from the American Heart Association

Diane Treat-Jacobson, Mary M. McDermott, Ulf G Bronas, Umberto Campia, Tracie C. Collins, Michael H. Criqui, Andrew W. Gardner, William R. Hiatt, Judith G. Regensteiner, Kathleen Rich

Research output: Contribution to journal › Article › peer-review

173 Scopus citations

Original language	English (US)
Pages (from-to)	E10-E33
Journal	Circulation
Volume	139
Issue number	4
DOIs	https://doi.org/10.1161/CIR.0000000000000623
State	Published - Jan 22 2019

Bibliographical note

Funding Information:
AstraZeneca (clinical trial research grant to study ticagrelor in PAD)*; Bayer (clinical trial research grant to study rivaroxaban in PAD)†; Pluristem (clinical research grant of a stem cell product in PAD)*; NIH (multicenter clinical trial in venous thrombosis)†

Funding Information:
ACI Medical (supplied pneumatic compression devices for a pilot study)*; Chromadex (supplied drug for study)†; Hershey’s Company (supplied drug for study)†; NHLBI (funding from 4 ongoing research grants)†; NIA†; PCORI†; Regeneron†; Reserveage (supplied drug for study on resveratrol)*; Viromed (supplied drug for study)†

Keywords

AHA Scientific Statements
exercise
exercise therapy
intermittent claudication
peripheral artery disease

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1161/CIR.0000000000000623

OpenUrl availability

Full text

Cite this

Treat-Jacobson, D., McDermott, M. M., Bronas, U. G., Campia, U., Collins, T. C., Criqui, M. H., Gardner, A. W., Hiatt, W. R., Regensteiner, J. G., & Rich, K. (2019). Optimal Exercise Programs for Patients with Peripheral Artery Disease: A Scientific Statement from the American Heart Association. Circulation, 139(4), E10-E33. https://doi.org/10.1161/CIR.0000000000000623

@article{551dca20640d42c0b70bf3b7be3d919a,

title = "Optimal Exercise Programs for Patients with Peripheral Artery Disease: A Scientific Statement from the American Heart Association",

keywords = "AHA Scientific Statements, exercise, exercise therapy, intermittent claudication, peripheral artery disease",

author = "Diane Treat-Jacobson and McDermott, {Mary M.} and Bronas, {Ulf G} and Umberto Campia and Collins, {Tracie C.} and Criqui, {Michael H.} and Gardner, {Andrew W.} and Hiatt, {William R.} and Regensteiner, {Judith G.} and Kathleen Rich",

note = "Funding Information: AstraZeneca (clinical trial research grant to study ticagrelor in PAD)*; Bayer (clinical trial research grant to study rivaroxaban in PAD)†; Pluristem (clinical research grant of a stem cell product in PAD)*; NIH (multicenter clinical trial in venous thrombosis)† Funding Information: ACI Medical (supplied pneumatic compression devices for a pilot study)*; Chromadex (supplied drug for study)†; Hershey{\textquoteright}s Company (supplied drug for study)†; NHLBI (funding from 4 ongoing research grants)†; NIA†; PCORI†; Regeneron†; Reserveage (supplied drug for study on resveratrol)*; Viromed (supplied drug for study)†",

year = "2019",

month = jan,

day = "22",

doi = "10.1161/CIR.0000000000000623",

language = "English (US)",

volume = "139",

pages = "E10--E33",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Optimal Exercise Programs for Patients with Peripheral Artery Disease

T2 - A Scientific Statement from the American Heart Association

AU - Treat-Jacobson, Diane

AU - McDermott, Mary M.

AU - Bronas, Ulf G

AU - Campia, Umberto

AU - Collins, Tracie C.

AU - Criqui, Michael H.

AU - Gardner, Andrew W.

AU - Hiatt, William R.

AU - Regensteiner, Judith G.

AU - Rich, Kathleen

N1 - Funding Information: AstraZeneca (clinical trial research grant to study ticagrelor in PAD)*; Bayer (clinical trial research grant to study rivaroxaban in PAD)†; Pluristem (clinical research grant of a stem cell product in PAD)*; NIH (multicenter clinical trial in venous thrombosis)† Funding Information: ACI Medical (supplied pneumatic compression devices for a pilot study)*; Chromadex (supplied drug for study)†; Hershey’s Company (supplied drug for study)†; NHLBI (funding from 4 ongoing research grants)†; NIA†; PCORI†; Regeneron†; Reserveage (supplied drug for study on resveratrol)*; Viromed (supplied drug for study)†

PY - 2019/1/22

Y1 - 2019/1/22

KW - AHA Scientific Statements

KW - exercise

KW - exercise therapy

KW - intermittent claudication

KW - peripheral artery disease

UR - http://www.scopus.com/inward/record.url?scp=85060197141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060197141&partnerID=8YFLogxK

U2 - 10.1161/CIR.0000000000000623

DO - 10.1161/CIR.0000000000000623

M3 - Article

C2 - 30586765

AN - SCOPUS:85060197141

SN - 0009-7322

VL - 139

SP - E10-E33

JO - Circulation

JF - Circulation

IS - 4

ER -

Optimal Exercise Programs for Patients with Peripheral Artery Disease: A Scientific Statement from the American Heart Association

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Cite this